Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$4.16 USD
+0.12 (2.97%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $4.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADPT 4.16 +0.12(2.97%)
Will ADPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
Other News for ADPT
3 Precision Medicine Stocks Tailoring Treatments
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Adaptive Biotechnologies announces data on MRD assessment with clonoSEQ
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference